Related Experiment Video

Updated: Jun 23, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Rationale for ACE inhibition as an anti-ischaemic therapy

C J Pepine1

  • 1University of Florida College of Medicine, Gainesville 32610-0277, USA.

European Heart Journal
|August 26, 1998
PubMed

Insights

Angiotensin-converting enzyme (ACE) inhibition with quinapril improves endothelial function in patients with coronary artery disease. This cardiovascular disease treatment also reduces atherosclerosis progression and reverses smoking-induced endothelial damage.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Endothelial dysfunction is a key factor in cardiovascular diseases.
  • Tissue angiotensin-converting enzyme (ACE) significantly influences endothelial function and disease progression.
  • Previous studies show ACE inhibition benefits patients with myocardial ischemia and left ventricular dysfunction.

Purpose of the Study:

  • To investigate the effects of ACE inhibition with quinapril on endothelial function in patients with coronary artery disease and preserved left ventricular function.
  • To assess quinapril's impact on coronary atherosclerosis progression and smoking-related endothelial dysfunction.

Main Methods:

  • Clinical studies evaluating ACE inhibition.
  • Assessment of endothelial function in large and small vessels.
  • Monitoring of coronary atherosclerosis progression in patients with hyperlipidemia.
  • Evaluation of quinapril's effects on endothelial function in smokers.

Main Results:

  • Quinapril improves endothelial function in both large and small vessels.
  • Quinapril inhibits coronary atherosclerosis progression in patients with high LDL cholesterol.
  • Quinapril reverses the adverse effects of smoking on endothelial function.
  • ACE inhibition demonstrates potential anti-ischemic effects.

Conclusions:

  • ACE inhibition with quinapril offers significant benefits for endothelial function in coronary artery disease patients with preserved left ventricular function.
  • Quinapril is effective in managing atherosclerosis and mitigating smoking-related endothelial damage.
  • Further research, like the QUINapril Anti-ischaemia and Symptoms of Angina Reduction trial, is ongoing to fully define quinapril's role in managing ischemia.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...